Latest Share Placement News

Control Bionics has locked in $9.5 million through a discounted share placement, complemented by a $0.5 million Share Purchase Plan, to back its commercial growth and technology development.

Imagion Biosystems has raised $3.75 million to fund the start of its Phase 1b/2 clinical trial for the MagSense HER2 imaging agent in the US, following FDA clearance. The capital raising involves a two-tranche share placement with free attaching options, led by CPS Capital.

Kingston Resources launches a $8.47 million rights issue at a 12.5% discount, backed by a $4.4 million placement, to finance a major drilling campaign and plant expansion at Mineral Hill following the closure of its Pearse South open pit.

Taiton Resources has allocated over 700,000 shares to its insiders following shareholder approval, with further shares and options pending issuance.

Australian Oil Company Limited has closed its Share Purchase Plan, raising $155,000 by issuing over 54 million shares at $0.0029 each, to support ongoing exploration in Queensland’s Surat Basin.

Hastings Technology Metals has secured a $1 million strategic placement from Malaco Mining to bolster its rare earth projects in Australia and Thailand, enhancing balance sheet flexibility and downstream processing ambitions.

Provaris Energy has raised $1 million through a share placement to fund key 2026 development milestones in hydrogen and liquid CO2 storage, reinforcing its technical progress and partnerships.

Daly Resources has posted a $352,743 loss for FY2025 amid aggressive expansion of its exploration portfolio, including the acquisition of the Huckitta and North Batten projects. The company is gearing up for a $10 million IPO in 2026 to fund its base metals and fluorite exploration ambitions.

Adherium Limited secured shareholder approval for all resolutions at its June 19, 2026 Extraordinary General Meeting, including a pivotal 1-for-100 share consolidation and approvals tied to recent capital raises and director participation.

Dotz Nano has secured A$3.3 million through a private placement, backing its next phase of production scale-up and customer engagement under incoming CEO Nati Harpaz.

Microba Life Sciences is targeting a $6 million capital raise through a $1 million Securities Purchase Plan and a $5 million Placement, both subject to shareholder approval. The funds aim to accelerate diagnostics growth and develop a new testing product.

Memphasys has secured $1.2 million through a share placement to support the global expansion and manufacturing scale-up of its Felix™ sperm selection system. The company also extended a major convertible note, reinforcing financial flexibility amid growing international contracts.